Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Xcel Energy Inc (XEL) Price & Performance

Cytokinetics IncTrade
Xcel Energy IncTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Xcel Energy Inc — how do they compare? Cytokinetics Inc trades at $76.7 (market cap $10.63B), while Xcel Energy Inc trades at $78 (market cap $48.51B). The key difference: Xcel Energy Inc is far larger — about 4.6× Cytokinetics Inc's market cap, and Xcel Energy Inc pays a 3.05% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKXEL
Market Cap
$10.63B$48.51B
Sector
TechnologyUtilities
52-Week High
$87.26$83.91
52-Week Low
$34.31$71.75
Enterprise Value
$10.74B$86.82B
Dividend Yield
3.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Xcel Energy Inc

Xcel Energy (XEL) trades at $76.87, down 1.54% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, and maintains a solid dividend. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%, while analyst consensus is bullish with a $93.80 price target.

The outlook is supported by earnings growth and a $60 billion capital investment plan, but risks include regulatory pushback and high debt levels. The stock offers a stable investment opportunity with growth potential from infrastructure spending, though affordability concerns and interest rate sensitivity pose challenges.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Xcel Energy Inc

Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan

Read more on XEL